Trump Administration Drug Price Cuts Impact Teva Pharmaceuticals
The Trump administration is expanding its program to lower prescription drug prices for Medicaid recipients, with Israeli pharmaceutical company Teva among the 26 firms that have reached agreements with the U.S. government. The policy, part of the "GENERATIONS" Medicaid model, allows states to negotiate drug prices based on those in other developed nations. All 50 U.S. states are expected to participate.
For Teva, the impact is mixed. As one of the world's largest generic drug manufacturers, its generics business aligns with the administration's goal of reducing drug costs and increasing competition. This segment of Teva's operations is not expected to face significant pressure from the new policy. However, the company's more profitable branded drugs, which have seen significant growth in recent years, could be affected.
Teva has not disclosed which specific drugs are included in the agreement, the extent of the discounts, or the projected impact on revenue. While generics are generally seen as a solution to lower healthcare spending, Teva's increasing reliance on branded drugs like AUSTEDO, AJOVY, and UZEDY presents a potential risk. These innovative drugs accounted for nearly half of Teva's U.S. revenue in the first half of 2026, with AUSTEDO being a primary growth driver.
The agreement also includes Teva's commitment to supply active pharmaceutical ingredients to the U.S. and support the strengthening of the domestic supply chain. This could bolster Teva's position as a key supplier to the American healthcare system, especially given the administration's focus on reducing reliance on foreign manufacturing.
The primary concern for investors remains which of Teva's branded drugs will be subject to the new pricing mechanism and the magnitude of the resulting discounts. While the policy affects only a portion of the U.S. market through Medicaid, it could still impact Teva's overall profitability if its high-growth innovative drugs are included.
